Technical Analysis for STRO - Sutro Biopharma, Inc.

Grade Last Price % Change Price Change
C 4.16 0.48% 0.02
STRO closed up 0.48 percent on Thursday, November 7, 2024, on approximately normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: Nov 11
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Lizard Bearish Bearish Day Trade Setup 0.00%
Calm After Storm Range Contraction 0.00%
Doji - Bearish? Reversal 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%

   Recent Intraday Alerts

Alert Time
Up 1 ATR about 4 hours ago
Up 5% about 6 hours ago
Rose Above Previous Day's High about 8 hours ago
Up 3% about 8 hours ago
Up 2% about 8 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Sutro Biopharma, Inc. Description

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Biology Immunology Antibodies Cancer Treatment Drug Discovery Lymphoma Antineoplastic Drugs Multiple Myeloma Autoimmune Disorders Immune Disorders Endometrial Cancer Immunogen Therapeutics For Cancer Hodgkin Lymphoma Milatuzumab Non Hodgkin Lymphoma Ovarian And Endometrial Cancers

Is STRO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.13
52 Week Low 2.005
Average Volume 568,671
200-Day Moving Average 4.02
50-Day Moving Average 3.80
20-Day Moving Average 3.68
10-Day Moving Average 3.68
Average True Range 0.26
RSI (14) 64.16
ADX 17.8
+DI 30.45
-DI 16.75
Chandelier Exit (Long, 3 ATRs) 3.62
Chandelier Exit (Short, 3 ATRs) 4.01
Upper Bollinger Bands 4.11
Lower Bollinger Band 3.25
Percent B (%b) 1.06
BandWidth 23.54
MACD Line 0.05
MACD Signal Line -0.03
MACD Histogram 0.0807
Fundamentals Value
Market Cap 253.57 Million
Num Shares 61 Million
EPS -2.91
Price-to-Earnings (P/E) Ratio -1.43
Price-to-Sales 5.98
Price-to-Book 2.54
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.61
Resistance 3 (R3) 4.64 4.53 4.54
Resistance 2 (R2) 4.53 4.41 4.51 4.51
Resistance 1 (R1) 4.34 4.34 4.44 4.31 4.48
Pivot Point 4.23 4.23 4.27 4.21 4.23
Support 1 (S1) 4.04 4.11 4.14 4.01 3.84
Support 2 (S2) 3.93 4.04 3.91 3.81
Support 3 (S3) 3.74 3.93 3.79
Support 4 (S4) 3.71